Clinical trials

Condition   Drug Name  
Study Efalizumab in pyoderma gangrenosum
Patients 1
Treatment Regimen Efalizumab, 0.7 mg/kg s.c. --> 1 mg/kg 1x/wk
Conclusions Efalizumab was associated with complete healing of multiple lesions of pyoderma gangrenosum and clearance of psoriatic lesions
Reference(s) Successful treatment of recalcitrant pyoderma gangrenosum with raptiva
16th Congr Eur Acad Dermatol Venereol (EADV) (May 16 2007 , Vienna) 2007:Abst P1136.
Author and Affiliation Gulliver, W.